Yifan Li

China

Dr Li has ertise in management and passion in improving the prognosis and quality of life of patients of gastric cancer.

Member of Shanxi Anti-Cancer Association.

Natalia Neparidze

USA

Dr. Neparidze serves as an Associate Professor and the leader of Yale Myeloma Research team. She has developed multiple research projects in myeloma, including a number of investigator-initiated therapeutic clinical trials. She serves as a PI and co-PI on multiple therapeutic clinical trials and leads several clinical outcomes studies in patients with myeloma. Her ongoing research directions include use of advanced imaging and evaluating tumor heterogeneity to enhance precision medicine approaches for myeloma, novel combination immunotherapy strategies and MRD-driven therapies in myeloma, as well as studying biology and clinical outcomes of monoclonal gammopathies in association with metabolic, viral and other co-morbidities, investigating mechanisms of tumor progression and resistance in myeloma.

Shunfu Hu

USA

Dr. Shunfu Hu is a Professor of Geography and Geograohic Information Sciences, Southern Illinois University Edwardsville, USA. He has recently worked on public health data sets for the purpose of visualizing the spatiotemporal patterns of the morality rates of many diseases, including cancer.

Jagadananda Ghosh

USA

Dr. Ghosh is a Senior Scientist at the Henry Ford Hospital in Detroit, Michigan, USA. The primary focus of his research is to understand the mechanisms underlying resistance to anticancer therapies. Recently, his team made a groundbreaking observation that the Tribbles 2 pseudokinase confers resistance to anti-androgens by driving neuroendocrine trans-differentiation. He is keenly interested to explore downstream mechanisms of Tribbles 2 and develop novel agents to overcome therapeutic resistance by targeting Tribbles 2. Dr. Ghosh is an internationally renowned scientist and would like to share recent results related to mechanism-based development of a new therapy for aggressive, drug-resistant, lethal prostate cancer.

Ernest Kaninjing

USA

Dr. Ernie Kaninjing is an Associate Professor of Public Health at Georgia College and State University in Milledgeville GA. He is a behavioral health scientist with expertise in prostate cancer outcomes research. His research explores the “within-group” differences in prostate cancer outcomes. Furthermore, His research examines the impact of immigration on prostate cancer outcomes among sub-Saharan African Immigrants and Caribbean Immigrants in the United States.

Thorsten Schaefer

Switzerland

The presenting author, Thorsten Schaefer (PD Dr.) is a senior researcher and lecturer at the University and University Hospital Basel, Switzerland. A biochemist by training, Dr. Schaefer specializes in PI3K/AKT signaling and the molecular-functional regulation of the stem cell factor SOX2. He is a standing member of the DGHO, AACR, ACS and The Biochemical Society, London, with documented research track in industry and academia. Dr. Constantin and Dr. Bissegger are two postdoctoral researchers in his team. The work presented was funded by KFS-4852082019R and SNF-10.004.128. Dr. Schaefer declares no conflicting interests. OMID-ID: 0000-0003-4867-8374.

Gulcin Ertas

Turkey